Japan for movers taking long-term medication

Evidence for moving and living here. The group label does not establish reviewed coverage.

Draft research. Check the sources, dates and recorded gaps.

Not yet covered

The short answer

What does the evidence say about this move?

Japan's Stimulants Control Act Article 13 prohibits stimulant import and export. Amphetamine and lisdexamfetamine have different classifications and rules. Do not treat all ADHD medicines as one class-wide prohibition. Confirm the exact ingredient and resident treatment plan with the Narcotics Control Department before moving.

e-Gov Law Search, Japan · Stimulants Control Act, Articles 13 and 30-6 · Retrieved

national · As of

What should I know?

No reviewed material-blocker conclusion is recorded. Unknown evidence must not be read as reassurance.

Confirm residence permission, healthcare access, and any treatment continuity before committing.

Serious barrier

amphetamine. prohibited for personal import under Stimulants Control Act Article 13. This is an ingredient-specific caution, not a finding about every medicine in the class.

Authority Ministry of Health, Labour and Welfare, Narcotics Control Department. Checked 27 October 2026. Confirm with The Narcotics Control Department covering the intended arrival airport, and the treating clinician.

e-Gov Law Search, Japan. Digital Agency law data service · Stimulants Control Act, Article 13. Current text through the e-Gov law API · Retrieved

Which factors change the answer?

Recorded factors for Japan
FindingStateScope and dateSource and first action
Japan's Stimulants Control Act Article 13 prohibits stimulant import and export. Amphetamine and lisdexamfetamine have different classifications and rules. Do not treat all ADHD medicines as one class-wide prohibition. Confirm the exact ingredient and resident treatment plan with the Narcotics Control Department before moving.Preparation requiredlaw · national · 18 October 2026e-Gov Law Search, Japan · Stimulants Control Act, Articles 13 and 30-6 · Retrieved Confirm the finding with its issuing authority.
Each finding keeps its own scope. Research drafts keep their source dates and unresolved gaps visible.

What do we know about general crime?

General crime evidence is not recorded for this guide. National crime figures cannot establish circumstance-specific safety.

What is daily treatment like?

Reviewed lived-experience evidence is not recorded. Legal rights alone do not establish everyday treatment.

Which rights and restrictions matter?

Japan's Stimulants Control Act Article 13 prohibits stimulant import and export. Amphetamine and lisdexamfetamine have different classifications and rules. Do not treat all ADHD medicines as one class-wide prohibition. Confirm the exact ingredient and resident treatment plan with the Narcotics Control Department before moving.

law · national · As of 18 October 2026

e-Gov Law Search, Japan · Stimulants Control Act, Articles 13 and 30-6 · Retrieved

How do I check medication continuity?

amphetamine

Serious barrier

prohibited for personal import under Stimulants Control Act Article 13

Authority Ministry of Health, Labour and Welfare, Narcotics Control Department. Checked 27 October 2026. Confirm with The Narcotics Control Department covering the intended arrival airport, and the treating clinician.

  • No personal import permission is established for this prohibited ingredient.
  • Confirm an appropriate continuing treatment plan with the treating clinician before moving.
e-Gov Law Search, Japan. Digital Agency law data service · Stimulants Control Act, Article 13. Current text through the e-Gov law API · Retrieved
Draft research. Source text is retained, but source-rights and specialist review have not taken place. The exact legal classification requires specialist confirmation. This record does not cover every stimulant medicine or establish local prescribing access. Foreign-prescription recognition and resident supply remain unknown. English summary is a researcher translation. The Japanese primary-law text controls. Article 30-6 sets a separate permission route for travellers carrying medicines that are stimulant raw materials. This record does not decide whether a specific medicine is a stimulant or a stimulant raw material.

Which national residence rules should I check?

Nationality applicability, dependants, healthcare, and work conditions belong to each official route. They require separate confirmation.

No route record is available. This does not establish that no route exists.

What remains unknown?

  • This is narrow draft research. It is not baseline or reviewed country coverage.
  • All unrecorded residence, nationality, family, work, healthcare, and circumstance rules remain unknown.
  • An individual medicine import rule does not establish resident supply or foreign-prescription recognition.
  • Independent specialist review, reusable-source rights approval, and retained snapshots are missing.
  • This finding describes the named national requirement. It does not establish personal applicability, daily treatment, or safety.
  • Current route-specific exemptions and the individual assessment need confirmation.
  • Independent specialist review and a retained source snapshot are missing.
  • Local conditions and personal circumstances can differ from the national finding.

Coverage completion does not establish publication approval.

Sources and verification

Research updated · Check the source and recorded gaps

e-Gov Law Search, Japan · Stimulants Control Act, Articles 13 and 30-6 · Retrieved Read the methodology